Evidence map›Paper›PMID 30715803›Full record

ArticleThe FEBS journal2019

A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53

Lukasz Skalniak, Aleksandra Twarda-Clapa, Constantinos G Neochoritis, Ewa Surmiak, Monika Machula, Aneta Wisniewska, Beata Labuzek, Ameena M Ali, Sylwia Krzanik, Grzegorz Dubin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The FEBS journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lukasz SkalniakFaculty of Chemistry, Jagiellonian University, Krakow, Poland.ORCID 0000-0002-6707-6697
Aleksandra Twarda-ClapaFaculty of Chemistry, Jagiellonian University, Krakow, Poland.
Constantinos G NeochoritisDepartment of Drug Design, University of Groningen, The Netherlands.
Ewa SurmiakFaculty of Chemistry, Jagiellonian University, Krakow, Poland.ORCID 0000-0002-4103-4675
Monika MachulaFaculty of Chemistry, Jagiellonian University, Krakow, Poland.
Aneta WisniewskaFaculty of Chemistry, Jagiellonian University, Krakow, Poland.
Beata LabuzekFaculty of Chemistry, Jagiellonian University, Krakow, Poland.
Ameena M AliDepartment of Drug Design, University of Groningen, The Netherlands.
Sylwia KrzanikFaculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Grzegorz DubinFaculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Matthew GrovesDepartment of Drug Design, University of Groningen, The Netherlands.
Alexander DömlingDepartment of Drug Design, University of Groningen, The Netherlands.
Tad A HolakFaculty of Chemistry, Jagiellonian University, Krakow, Poland.

Funding

Real-time discovery of inhibitors among billion compounds for preview and downloadR01GM097082 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMACHO, CARLOS J. · 2011 to 2020
$2.5M
NIGMS NIH HHS R01 GM097082
6 · The paper itself

Abstract

The p53 protein is engaged in the repair of DNA mutations and elimination of heavily damaged cells, providing anticancer protection. Dysregulation of p53 activity is a crucial step in carcinogenesis. This dysregulation is often caused by the overexpression of negative regulators of p53, among which MDM2 is the most prominent one. Antagonizing MDM2 with small molecules restores the activity of p53 in p53 wild-type (p53

Indexed as

Antineoplastic AgentsApoptosisBone NeoplasmsCell ProliferationHalogenationHumansIndolesOsteosarcomaProtein BindingProtein ConformationProto-Oncogene Proteins c-mdm2Structure-Activity RelationshipTumor Cells, CulturedTumor Suppressor Protein p53Antineoplastic AgentsIndolesMDM2 protein, humanProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53MDM2 antagonistmulticomponent reactionp53targeted therapyUgi reaction

Identifiers

PMID30715803
PMCPMC6634946

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.